GoldenGolden
Advanced Search
Commence Bio

Commence Bio

Commence Bio is a biotechnology company developing immunotherapies using stem cells for treating cancer and inflammatory diseases.

Commence Bio is a therapeutics company that is developing methods to enhance the anti-inflammatory properties of stem cells. The company aims to apply these methods in various inflammation-related disorders that include rheumatoid arthritis, by creating cellular therapeutics with predictable behaviors.

The company's technology is used to change adult, allogeneic mesenchymal stem cells into powerful immunomodulators that migrate to the sites of immune dysfunction through a multi-pronged effect and re-awakening the body's innate and adaptive immune responses, allowing patients to get treatments for cancer and inflammatory diseases by rebooting the immune systems of patients with cell therapies.

Commence Bio has the vision that cancer and inflammatory diseases can be treated by rebooting patients' immune systems with a new class of medicinal stem cells: MSC1 & MSC2. Using its proprietary Stimulated Toll-like Receptor Technology [STaRT™], adult, allogeneic mesenchymal stem cells [MSCs] are transformed into powerful immunomodulators that migrate to the sites of dysfunction and. through a multi-pronged effect, reboot an appropriate immune response.

Timeline

People

Name
Role
LinkedIn

Aline Betancourt

Co-Founder

Tom Isett

Co-Founder & CEO

Further reading

Title
Author
Link
Type
Date

Commence Bio Finalizes Corporate Identity Change From WibiWorks Therapeutics and Introduces New Website

Commence Bio

Web

Novel Cancer Immunotherapy Technology by Commence Bio Receives Patent - Immuno-Oncology News

Patricia Inacio

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.